Dutch di­ag­nos­tics play­er Qi­a­gen con­firms buy­out talks fol­low­ing re­port of Ther­mo Fish­er's in­ter­est

Sev­er­al bid­ders have laid their eyes on Dutch di­ag­nos­tics firm Qi­a­gen — and Ther­mo Fish­er is re­port­ed­ly one of them.

Qi­a­gen, which is list­ed on the NYSE, no­ti­fied in­vestors on Fri­day that “it has be­gun a re­view of po­ten­tial strate­gic al­ter­na­tives af­ter re­ceiv­ing sev­er­al con­di­tion­al, non-bind­ing in­di­ca­tions of in­ter­est for the ac­qui­si­tion of all is­sued and out­stand­ing shares of the Com­pa­ny.” It didn’t name any of the po­ten­tial buy­ers.

The board is in dis­cus­sions with these in­ter­est­ed par­ties, the com­pa­ny added.

Peer Schatz

Shares $QGEN are up a fur­ther 12% to $42.2 af­ter a surge ear­li­er in the week, in re­sponse to a Bloomberg re­port — based on in­sid­er in­for­ma­tion — that Ther­mo Fish­er is con­sid­er­ing a takeover. Qi­a­gen’s mar­ket cap now stands at $9.19 bil­lion.

If Ther­mo Fish­er pre­vails, this could mark one of the con­glom­er­ate’s largest pur­chas­es, Bloomberg not­ed, sur­pass­ing the $7.2 bil­lion deal for con­tract de­vel­op­ment and man­u­fac­tur­ing group Pan­theon.

Head­quar­tered in Ven­lo, The Nether­lands, with over 5,200 staffers spread across 35 of­fices glob­al­ly, Qi­a­gen has built a suite of ge­nom­ic analy­sis ser­vices around tech­nolo­gies that iso­late and process DNA, RNA and pro­teins from blood, tis­sue or oth­er sam­ples.

The po­ten­tial buy­out comes at a time of flux for the com­pa­ny. Just a month ago, CEO Peer Schatz hand­ed in his no­tice af­ter start­ing as one of Qi­a­gen’s first em­ploy­ees 27 years ago, trig­ger­ing a search for his suc­ces­sor. Thier­ry Bernard, head of the mol­e­c­u­lar di­ag­nos­tics unit, is in charge ad in­ter­im.

“Our Life Sci­ences port­fo­lio is fac­ing ac­cel­er­at­ing growth, our Mol­e­c­u­lar Di­ag­nos­tics port­fo­lio is to­day sec­ond to none in terms of com­pet­i­tive pro­file, and now strength­ened by our new strate­gic part­ner­ship with Il­lu­mi­na, and our bioin­for­mat­ics port­fo­lio has tak­en a strong and in­dus­try-defin­ing po­si­tion in dig­i­tal so­lu­tions to gain mol­e­c­u­lar in­sights. We have a lot of op­por­tu­ni­ties and are en­ter­ing in­to a new chap­ter of the QI­A­GEN growth sto­ry,” Schatz, who re­mains a spe­cial ad­vi­sor, said at the time. “And this is why, af­ter 27 fan­tas­tic years at QI­A­GEN, I now see a nat­ur­al in­flec­tion point to bring in new lead­er­ship and will sup­port this process.”

So­cial im­age: Qi­a­gen

Tal Zaks, Moderna CMO (Moderna via YouTube)

UP­DAT­ED: NI­AID and Mod­er­na spell out a 'ro­bust' im­mune re­sponse in PhI coro­n­avirus vac­cine test — but big ques­tions re­main to be an­swered

The NIAID and Moderna have spelled out positive Phase I safety and efficacy data for their Covid-19 vaccine mRNA-1273 — highlighting the first full, clear sketch of evidence that back-to-back jabs at the dose selected for Phase III routinely produced a swarm of antibodies to the virus that exceeded levels seen in convalescent patients — typically in multiples indicating a protective response.

Moderna execs say plainly that this first stage of research produced exactly the kind of efficacy they hoped to see in humans, with a manageable safety profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Trans­port Sim­u­la­tion Test­ing for Your Ther­a­py is the Best Way to As­sure FDA Ex­pe­dit­ed Pro­gram Ap­proval

Modality Solutions is an ISO:9001-registered biopharmaceutical cold chain engineering firm with unique transport simulation capabilities that support accelerated regulatory approval for biologics and advanced therapeutic medicinal products (ATMP). Our expertise combines traditional validation engineering approaches with regulatory knowledge into a methodology tailored for the life sciences industry. We provide insight and execution for the challenges faced in your cold chain logistics network.

Source: Shutterstock

Who are the women blaz­ing trails in bio­phar­ma R&D and lead­ing the fight against Covid-19? Nom­i­nate them for End­points' spe­cial re­port

One of the many inequalities the pandemic has laid bare is the gender imbalance in biomedical research. A paper examining Covid-19 research authorship wondered out loud: Where are the women?

It’s a question that echoes beyond our current times. In the biopharma world, not only are women under-represented in R&D roles (particularly at higher levels), their achievements and talents could also be undermined by stereotypes and norms of leadership styles. The problem is even more dire for women of color.

Donald Trump and Anthony Fauci (AP Images)

Covid-19 roundup: Fau­ci fires back at White House cam­paign to un­der­mine him

Anthony Fauci has called the White House campaign to discredit him “a bit bizarre” and said he stands by his previous statements, even if he has since changed his views.

The NIAID chief — who has received an outpouring of support following reports that the Trump administration has sent a document akin to opposition research to multiple news outlets — spoke with his usual candor in interviews with The Atlantic.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

De­spite safe­ty, ef­fi­ca­cy con­cerns, FDA Ad­Com nar­row­ly rec­om­mends Mallinck­rodt drug

A day after the FDA detailed significant concerns about just how effective or safe an experimental Mallinckrodt liver drug was, an advisory committee decided by a single vote to recommend it for approval.

“I voted yes to approve, but I also wrote in, ‘but barely,’” Paul Ridker, a cardiologist at Brigham and Women’s Hospital and one of the panelists, said at the meeting, according to FierceBiotech. The vote was 8-7.

John Furey, Imvax CEO

A neu­ro­sur­geon spent the past 30 years de­vel­op­ing a neoanti­gen tu­mor vac­cine. Now he has $112M to put it to piv­otal test

As a neurosurgeon, David Andrews knew there wasn’t much he could do for his glioma patients after resecting — rarely fully — their tumor. Even with the best treatment and care available, median overall survival is just somewhere between 14 and 16 months.

Then in the 1990s, his mentor at Thomas Jefferson University introduced him to Renato Baserga, a pathologist who had been studying the effect of using antisense oligonucleotide to knock out the insulin-like growth factor type 1 receptor in cancers. As IGF-R1 drives tumor growth and metastasis, the preclinical reasoning went, implanting a molecule targeting the receptor together with the tumor material near lymph nodes can slow down the spread of the cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Jeff Albers, Blueprint CEO

Di­ag­nos­tic champ Roche buys its way in­to the RET ti­tle fight with Eli Lil­ly, pay­ing $775M in cash to Blue­print

When Roche spelled out its original $1 billion deal — $45 million of that upfront — with Blueprint to discover targeted therapies against immunokinases, the biotech partner’s RET program was still preclinical. Four years later, pralsetinib is on the cusp of potential approval and the Swiss pharma giant is putting in much more to get in on the commercial game.

Roche gains rights to co-develop and co-commercialize the drug, with sole marketing responsibility for places outside the US and China (where CStone has staked its claim).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 85,300+ biopharma pros reading Endpoints daily — and it's free.

Sanjiv Patel, Relay CEO

Re­lay reaps $400M IPO wind­fall af­ter draw­ing the cur­tain on mo­tion-based drug de­sign pipeline

A red-hot venture market back in 2018 propelled Relay Therapeutics to a whopping $400 million crossover round. And now, the biotech is riding on a red-hot IPO market to a public debut that brought in the same exact amount.

The $400 million raise breaks down to 20 million shares sold at $20 each — above even the amended proposed range of $16 to $18.

It’s also double what Relay had penciled in with the initial S-1 filing, in yet another illustration that those figures are often nothing more than a placeholder these days.

BioAt­la rakes in $72.5M Se­ries D, ad­vanc­ing re­search for pH-de­tect­ing can­cer treat­ments

A little over a year after agreeing to a worldwide collaboration with hefty Chinese biotech BeiGene worth up to $270 million, BioAtla is ready for another haul.

The San Diego-based biotech pulled in a $72.5 million haul for their Series D financing, which the company announced Wednesday. Funds will go toward their four main clinical programs developing cancer treatments, two of which are currently in Phase II, BioAtla president and former Celgene COO Scott Smith said.